Heart Pump Devices Market Report 2025

The heart pump devices market size has grown rapidly in recent years. It will grow from $3.79 billion in 2024 to $4.5 billion in 2025 at a compound annual growth rate (CAGR) of 18.8%. The growth in the historic period can be attributed to increased prevalence of cardiovascular diseases, aging population, awareness and education, government initiatives and funding, improved surgical techniques.

The heart pump devices market size is expected to see rapid growth in the next few years. It will grow to $8.86 billion in 2029 at a compound annual growth rate (CAGR) of 18.4%. The growth in the forecast period can be attributed to rising global healthcare expenditure, emerging markets and untapped opportunities, personalized medicine and customization, increasing regulatory approvals, growing patient awareness. Major trends in the forecast period include technological advancements, remote monitoring and connectivity, long-term mechanical support, miniaturization and portability, artificial intelligence integration.

The rising prevalence of cardiovascular disorders is anticipated to drive the growth of the heart pump devices market. Cardiovascular disorders encompass conditions affecting the heart and blood vessels. As the incidence of cardiovascular diseases rises, there will be a greater need for advanced diagnostics and treatments, including heart pump devices. These devices are essential for pumping blood from the lower left chamber of the heart, especially during high-risk protected percutaneous coronary interventions, thereby increasing market demand. For example, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government body, revealed that in 2023, over 1,862,500 individuals (3%) in England had a GP diagnosis of coronary heart disease (CHD). Notably, the proportion of individuals diagnosed with CHD has declined since the financial year ending in 2010. Thus, the increasing prevalence of cardiovascular disorders is fueling the growth of the heart pump devices market.

The increasing prevalence of chronic conditions such as heart attacks, diabetes, hypertension, and atrial fibrillation is anticipated to drive the growth of the heart pump devices market in the future. Chronic diseases are defined as conditions that typically last for three months or longer and may deteriorate over time. Some of the most common chronic diseases include cancer, heart disease, stroke, diabetes, and arthritis. Heart pump devices are designed to pump blood from the lower left chamber of the heart, assisting in maintaining blood flow during high-risk protected percutaneous coronary interventions, such as heart attacks and atrial fibrillation. For instance, data published by the New York government in December 2022 revealed that heart disease accounts for approximately 697,000 deaths annually in the United States, representing 1 in every 5 fatalities. Additionally, around 805,000 Americans experience a heart attack each year, of which 605,000 are first-time heart attacks, while 200,000 are due to previous incidents. Furthermore, the Centers for Disease Control and Prevention, a U.S.-based national public health agency, reported in 2022 that approximately 37.3 million people are affected by diabetes, which constitutes 11.3% of the U.S. population. Consequently, the rising incidence of chronic diseases is propelling the growth of the heart pump devices market.

Major companies in the heart pump devices market are concentrating on innovative technologies, such as self-expanding mechanisms, to enhance device efficiency, improve patient outcomes, and minimize the risk of complications during implantation. A self-expanding mechanism is a design that automatically expands to its full size upon deployment, utilizing materials or structures that facilitate this expansion without requiring additional external forces. For example, in June 2023, Magenta Medical, an Israeli company, introduced its groundbreaking heart pump technology by launching the world's smallest heart pump. The Elevate Pump is a percutaneous Left Ventricular Assist Device (VAD) that fits within an 8 French (Fr) delivery system, positioning it as one of the smallest devices in its category.

Major companies operating in the heart pump devices market are developing extracorporeal membrane oxygenation (ECMO) systems to provide advanced life support for patients with severe heart and lung conditions. Extracorporeal membrane oxygenation (ECMO) systems refer to advanced life support machines used to provide prolonged cardiac and respiratory support for patients whose heart and lungs are unable to function properly. For instance, in September 2024, Medtronic plc, an Ireland-based medical device company, launched VitalFlow system, an innovative extracorporeal membrane oxygenation (ECMO) solution designed to provide circulatory support for patients with severe heart or lung failure. The VitalFlow system functions as a heart pump by using a pump and oxygenator to take over the work of the heart and lungs. This is crucial for patients experiencing life-threatening conditions, allowing their organs to rest and heal.

In February 2022, Boston Scientific Corporation, a renowned US-based biomedical and biotechnology engineering firm, successfully acquired Baylis Medical Company Inc. for a substantial sum of $1.75 billion. Through this strategic acquisition, Boston Scientific aims to seamlessly integrate the innovative platforms of Baylis with its existing portfolio in electrophysiology and structural heart offerings. This strategic move is expected to fortify Boston Scientific's position within the competitive cardiology market, enhancing its capabilities in providing advanced solutions for cardiovascular care. Baylis Medical Company Inc., based in Canada, is recognized for its expertise in manufacturing heart pump devices.

Major companies operating in the heart pump devices market are MedtronicPLC, Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Getinge AB, Cardiomedix, ReliantHeart, CardiacAssist, SynCardia Systems, CARMAT, Sorin Group, BiVACOR, Bristol-Myers Squibb, MicroMed Cardiovascular, Aortica Corporation, Fresenius Kabi, Acelity, Asahi Kasei Medical, LivaNova, HeartWare International, Jarvik Heart, MediCardia, Avinger, Nuvectra, OrbusNeich, Ventracor, EBR Systems, and CorWave.

North America was the largest region in the heart pump devices market share in 2024. The regions covered in the heart pump devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the heart pump devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A heart pump device is a mechanical support device designed to assist in pumping blood from the heart chambers to the rest of the body, temporarily aiding the heart's pumping action.

Heart pump devices come in two main types including implantable heart pump devices and extracorporeal heart pump devices. Implantable heart pump devices are mechanical pumps surgically implanted in the chest to assist a weakened heart in pumping blood. These devices serve various therapeutic purposes, including bridge-to-transplant (BTT), bridge-to-candidacy (BTC), destination therapy (DT), and others. Heart pump devices find applications in diverse healthcare settings, including hospitals, ambulatory surgical centers, specialty clinics, and more.

The heart pump devices market research report is one of a series of new reports that provides heart pump devices market statistics, including the heart pump devices industry’s global market size, regional shares, competitors with a Heart pump devices market share, detailed heart pump devices market segments, market trends and opportunities, and any further data you may need to thrive in the heart pump devices industry. This heart pump devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The heart pump devices market consists of sales of pacemakers, biventricular devices, cardioverter defibrillators, and mechanical assist devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.